Skip to main content
Top
Published in: European Radiology 2/2024

12-08-2023 | Hepatocellular Carcinoma | Hepatobiliary-Pancreas

3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma

Authors: Haiyi Long, Xiaoyu Zhou, Xiaoer Zhang, Jieyi Ye, Tongyi Huang, Longfei Cong, Xiaoyan Xie, Guangliang Huang

Published in: European Radiology | Issue 2/2024

Login to get access

Abstract

Purpose

To compare the efficiency of three-dimensional (3D) and two-dimensional (2D) contrast-enhanced ultrasound (CEUS)–derived techniques in evaluating the ablative margin (AM) after radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC).

Methods

In total, 98 patients with 98 HCCs were enrolled. The 2D CEUS point-to-point imaging (2D CEUS-PI) was conducted by comparing the pre- and post-RFA 2D CEUS images manually, and the 3D CEUS fusion imaging (3D CEUS-FI) was conducted by fusing the pre- and post-RFA 3D CEUS images automatically. These two techniques were compared in distinguishing an adequate AM ≥ 5 mm. Risk factors for local tumor progression (LTP) after RFA were analyzed by the Kaplan–Meier method with log-rank test.

Results

The mean registration time of 3D CEUS-FI and 2D CEUS-PI was 5.0 and 9.3 min, respectively (p < 0.0001). The kappa coefficient was 0.680 for agreement between 2D CEUS-PI and 3D CEUS-FI in the evaluation of AM (p < 0.0001). Tumors with AM < 5 mm by 2D CEUS-PI were all identified as AM < 5 mm by 3D CEUS-FI. Nonetheless, 16 (26%) tumors identified as AM ≥ 5 mm by 2D CEUS-PI were re-classified as AM < 5 mm by 3D CEUS-FI. During a median follow-up time of 31.2 months (range, 3.2–66.0 months), LTP was identified in 8 tumors. The estimated 1-/2-/3-year cumulative incidence of LTP was 4.4%, 8.1%, and 10.3%, respectively. Higher estimated cumulative incidence of LTP was identified in tumors with AM < 5 mm by 2D CEUS-PI (at 3-year, 27.2% vs 0%; p < 0.001), and by 3D CEUS-FI (at 3-year, 20.7% vs 0%; p = 0.004).

Conclusion

3D CEUS-FI excelled in the evaluation of AM when compared with 2D CEUS-PI. With equivalent efficacy in the prediction of LTP, 3D CEUS-FI was superior to 2D CEUS-PI for its automatic and time-saving procedure.

Clinical relevance statement

3D CEUS fusion imaging may serve as an effective tool in evaluating ablative margin and predicting local tumor progression after RFA in HCC.

Key Points

Both 2D and 3D CEUS–derived techniques could evaluate ablative margin (AM) after RFA for hepatocellular carcinoma.
3D CEUS fusion imaging was more precise in the evaluation of AM compared to 2D CEUS point-to-point imaging, with advantages of its automatic and time-saving procedure.
An inadequate AM < 5 mm evaluated by CEUS-derived techniques was the only risk factor of LTP after RFA for hepatocellular carcinoma (p < 0.001 for 2D CEUS point-to-point imaging, and p = 0.004 for 3D CEUS fusion imaging).
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed
2.
go back to reference Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76:681–693CrossRefPubMed Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76:681–693CrossRefPubMed
3.
go back to reference Takayama T, Hasegawa K, Izumi N et al (2022) Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial). Liver Cancer 11:209–218CrossRefPubMed Takayama T, Hasegawa K, Izumi N et al (2022) Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial). Liver Cancer 11:209–218CrossRefPubMed
4.
go back to reference Lee MW, Kang D, Lim HK et al (2020) Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 30:2391–2400CrossRefPubMed Lee MW, Kang D, Lim HK et al (2020) Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 30:2391–2400CrossRefPubMed
5.
go back to reference Sakakibara M, Ohkawa K, Katayama K et al (2014) Three-dimensional registration of images obtained before and after radiofrequency ablation of hepatocellular carcinoma to assess treatment adequacy. AJR Am J Roentgenol 202:W487-495CrossRefPubMed Sakakibara M, Ohkawa K, Katayama K et al (2014) Three-dimensional registration of images obtained before and after radiofrequency ablation of hepatocellular carcinoma to assess treatment adequacy. AJR Am J Roentgenol 202:W487-495CrossRefPubMed
6.
go back to reference Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A (2021) Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 46:5162–5179CrossRefPubMed Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A (2021) Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 46:5162–5179CrossRefPubMed
7.
go back to reference Kisaka Y, Hirooka M, Kumagi T et al (2006) Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 26:1241–1247CrossRefPubMed Kisaka Y, Hirooka M, Kumagi T et al (2006) Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 26:1241–1247CrossRefPubMed
8.
go back to reference Xu EJ, Lv SM, Li K et al (2018) Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia 34:870–876CrossRefPubMed Xu EJ, Lv SM, Li K et al (2018) Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia 34:870–876CrossRefPubMed
9.
go back to reference Ye J, Huang G, Zhang X et al (2019) Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. Int J Hyperthermia 36:55–64CrossRefPubMed Ye J, Huang G, Zhang X et al (2019) Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. Int J Hyperthermia 36:55–64CrossRefPubMed
10.
go back to reference Zhang X, Huang G, Ye J et al (2019) 3-D contrast-enhanced ultrasound fusion imaging: a new technique to evaluate the ablative margin of radiofrequency ablation for hepatocellular carcinoma. Ultrasound Med Biol 45:1933–1943CrossRefPubMed Zhang X, Huang G, Ye J et al (2019) 3-D contrast-enhanced ultrasound fusion imaging: a new technique to evaluate the ablative margin of radiofrequency ablation for hepatocellular carcinoma. Ultrasound Med Biol 45:1933–1943CrossRefPubMed
11.
go back to reference Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMed Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMed
12.
go back to reference Seror O, N’Kontchou G, Nault JC et al (2016) Hepatocellular carcinoma within milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results. Radiology 280:611–621CrossRefPubMed Seror O, N’Kontchou G, Nault JC et al (2016) Hepatocellular carcinoma within milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results. Radiology 280:611–621CrossRefPubMed
13.
go back to reference Yang Y, Chen Y, Ye F et al (2021) Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol 31:3053–3064CrossRefPubMed Yang Y, Chen Y, Ye F et al (2021) Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol 31:3053–3064CrossRefPubMed
14.
go back to reference Liu M, Huang GL, Xu M et al (2017) Percutaneous thermal ablation for the treatment of colorectal liver metastases and hepatocellular carcinoma: a comparison of local therapeutic efficacy. Int J Hyperthermia 33:446–453CrossRefPubMed Liu M, Huang GL, Xu M et al (2017) Percutaneous thermal ablation for the treatment of colorectal liver metastases and hepatocellular carcinoma: a comparison of local therapeutic efficacy. Int J Hyperthermia 33:446–453CrossRefPubMed
15.
go back to reference Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology 273:241–260CrossRefPubMed Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology 273:241–260CrossRefPubMed
16.
go back to reference Zheng H, Liu K, Yang Y et al (2022) Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study. Eur Radiol 32:4657–4666CrossRefPubMed Zheng H, Liu K, Yang Y et al (2022) Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study. Eur Radiol 32:4657–4666CrossRefPubMed
17.
go back to reference Choi D, Lim HK, Kim SH et al (2000) Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. Radiology 217:558–563CrossRefPubMed Choi D, Lim HK, Kim SH et al (2000) Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. Radiology 217:558–563CrossRefPubMed
18.
go back to reference Ahn SJ, Lee JM, Lee DH et al (2017) Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol 66:347–354CrossRefPubMed Ahn SJ, Lee JM, Lee DH et al (2017) Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol 66:347–354CrossRefPubMed
19.
go back to reference Song KD, Lee MW, Rhim H, Cha DI, Chong Y, Lim HK (2013) Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol 201:1141–1147CrossRefPubMed Song KD, Lee MW, Rhim H, Cha DI, Chong Y, Lim HK (2013) Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol 201:1141–1147CrossRefPubMed
20.
go back to reference Kisaka Y, Hirooka M, Koizumi Y et al (2010) Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. J Clin Ultrasound 38:138–144CrossRefPubMed Kisaka Y, Hirooka M, Koizumi Y et al (2010) Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. J Clin Ultrasound 38:138–144CrossRefPubMed
21.
go back to reference Bo XW, Xu HX, Guo LH et al (2017) Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers. Br J Radiol 90:20170063CrossRefPubMedPubMedCentral Bo XW, Xu HX, Guo LH et al (2017) Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers. Br J Radiol 90:20170063CrossRefPubMedPubMedCentral
22.
go back to reference Wang Y, Jing X, Ding J (2016) Clinical value of dynamic 3-dimensional contrast-enhanced ultrasound imaging for the assessment of hepatocellular carcinoma ablation. Clin Imaging 40:402–406CrossRefPubMed Wang Y, Jing X, Ding J (2016) Clinical value of dynamic 3-dimensional contrast-enhanced ultrasound imaging for the assessment of hepatocellular carcinoma ablation. Clin Imaging 40:402–406CrossRefPubMed
23.
go back to reference Cao J, Dong Y, Mao F, Wang W (2018) Dynamic three-dimensional contrast-enhanced ultrasound to predict therapeutic response of radiofrequency ablation in hepatocellular carcinoma: preliminary findings. Biomed Res Int 2018:6469703CrossRefPubMedPubMedCentral Cao J, Dong Y, Mao F, Wang W (2018) Dynamic three-dimensional contrast-enhanced ultrasound to predict therapeutic response of radiofrequency ablation in hepatocellular carcinoma: preliminary findings. Biomed Res Int 2018:6469703CrossRefPubMedPubMedCentral
24.
go back to reference Xu HX, Lu MD, Xie XH et al (2010) Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol 76:81–88CrossRefPubMed Xu HX, Lu MD, Xie XH et al (2010) Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol 76:81–88CrossRefPubMed
25.
go back to reference Chen J, Lin Z, Lin Q, Lin R, Yan Y, Chen J (2020) Percutaneous radiofrequency ablation for small hepatocellular carcinoma in hepatic dome under MR-guidance: clinical safety and efficacy. Int J Hyperthermia 37:192–201CrossRefPubMed Chen J, Lin Z, Lin Q, Lin R, Yan Y, Chen J (2020) Percutaneous radiofrequency ablation for small hepatocellular carcinoma in hepatic dome under MR-guidance: clinical safety and efficacy. Int J Hyperthermia 37:192–201CrossRefPubMed
26.
go back to reference Song KD, Lee MW, Rhim H et al (2018) Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology 288:878–886CrossRefPubMed Song KD, Lee MW, Rhim H et al (2018) Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology 288:878–886CrossRefPubMed
27.
go back to reference Vietti Violi N, Duran R, Guiu B et al (2018) Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 3:317–325CrossRefPubMed Vietti Violi N, Duran R, Guiu B et al (2018) Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 3:317–325CrossRefPubMed
28.
go back to reference Kim TH, Koh YH, Kim BH et al (2021) Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol 74:603–612CrossRefPubMed Kim TH, Koh YH, Kim BH et al (2021) Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol 74:603–612CrossRefPubMed
29.
go back to reference Yang Y, Chen Y, Zhang X et al (2021) Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: a multicenter retrospective study. Eur J Radiol 138:109623CrossRefPubMed Yang Y, Chen Y, Zhang X et al (2021) Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: a multicenter retrospective study. Eur J Radiol 138:109623CrossRefPubMed
30.
go back to reference Ikeda K, Seki T, Umehara H et al (2007) Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol 31:485–491PubMed Ikeda K, Seki T, Umehara H et al (2007) Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol 31:485–491PubMed
31.
go back to reference Nakazawa T, Kokubu S, Shibuya A et al (2007) Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 188:480–488CrossRefPubMed Nakazawa T, Kokubu S, Shibuya A et al (2007) Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 188:480–488CrossRefPubMed
32.
go back to reference Jiang C, Liu B, Chen S, Peng Z, Xie X, Kuang M (2018) Safety margin after radiofrequency ablation of hepatocellular carcinoma: precise assessment with a three-dimensional reconstruction technique using CT imaging. Int J Hyperthermia 34:1135–1141CrossRefPubMed Jiang C, Liu B, Chen S, Peng Z, Xie X, Kuang M (2018) Safety margin after radiofrequency ablation of hepatocellular carcinoma: precise assessment with a three-dimensional reconstruction technique using CT imaging. Int J Hyperthermia 34:1135–1141CrossRefPubMed
33.
go back to reference Kaye EA, Cornelis FH, Petre EN et al (2019) Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression. Eur Radiol 29:2698–2705CrossRefPubMed Kaye EA, Cornelis FH, Petre EN et al (2019) Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression. Eur Radiol 29:2698–2705CrossRefPubMed
34.
go back to reference Okusaka T, Okada S, Ueno H et al (2002) Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 95:1931–1937CrossRefPubMed Okusaka T, Okada S, Ueno H et al (2002) Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 95:1931–1937CrossRefPubMed
35.
go back to reference Hu HT, Wang Z, Huang XW et al (2019) Ultrasound-based radiomics score: a potential biomarker for the prediction of microvascular invasion in hepatocellular carcinoma. Eur Radiol 29:2890–2901CrossRefPubMed Hu HT, Wang Z, Huang XW et al (2019) Ultrasound-based radiomics score: a potential biomarker for the prediction of microvascular invasion in hepatocellular carcinoma. Eur Radiol 29:2890–2901CrossRefPubMed
Metadata
Title
3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma
Authors
Haiyi Long
Xiaoyu Zhou
Xiaoer Zhang
Jieyi Ye
Tongyi Huang
Longfei Cong
Xiaoyan Xie
Guangliang Huang
Publication date
12-08-2023
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 2/2024
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-023-10023-5

Other articles of this Issue 2/2024

European Radiology 2/2024 Go to the issue